Dallas, TX (PRWEB) October 28, 2013
Rosellini Scientific LLC, based in Dallas, TX, is pleased to announce the hire of Hartmut Spitaels, MSc.E, MBA as President of Rosellini Scientific Benelux S.A. in June 2013. His role in the company’s new European office in Brussels, Belgium is to enable international collaboration between Rosellini Scientific LLC and leading European clinicians and investors. Spitaels, a medical technology entrepreneur, brings over 11 years of experience in implantable devices to the Rosellini Scientific team. He specializes in the transition from development to first-in-man clinical proof.
“We are thrilled to have Spitaels join our company,” stated CEO Emily Rosellini, MD. “His expert guidance on regulatory and reimbursement pathways for the European market, as well as his vast network of key opinion leaders, suppliers, technology providers and investors, will be a main asset in Rosellini Scientific’s clinical validation of medical technology.”
Early in his career, Spitaels developed a non-invasive diagnostic tool for the monitoring of implantable heart prosthesis in collaboration with Saint Jude Medical. He sold an exclusive license of this diagnostic tool to the Centre for Experimental Surgery and Anesthesia (CEHA).
Spitaels was responsible for the joint collaboration between Cochlear Ltd. and the Laboratory for Micro-systems and Sensors at KuLeuven University. The collaboration yielded a successful MEMS-based electrode array for use in cochlear implants. This work led him to become CEO of a start-up, 3WIN N.V, where he developed an implantable neurostimulation platform. Spitaels was instrumental to the initial seed funding and raised in excess of seven mio Eur, including 3 mio grant money to support final development and clinical validation. The neurostimulator was successfully validated in clinical trials on 11 patients suffering from tinnitus and Dystonia.
He co-founded Synaptix N.V. in 2012 and served as Managing Director for the Antwerp-based company. The acquisition of 3WIN N.V. enabled Synaptix to commercialize and re-brand the implantable neurostimulation platform into a CE approved Deep Brain stimulator for treatment of Parkinson’s and other movement disorders.
Spitaels is an inventor on three patent applications in the field of implantable technology and is an accredited expert for the European Commission, Lifesciences Branch. He holds a Master of Science in Engineering and a Master in Biomedical Engineering and Technology, magna cum laude from the KuLeuven, Belgium. He graduated from the international MBA program at the Vlerick-Business School with great honor.
About Rosellini Scientific LLC
Rosellini Scientific invests both expertise and capital in the development of medical technology that utilizes electricity to alter the nervous system. The company collaborates with leading researchers and collaborates with pioneering universities and companies. As a global leader in the business of medical technology, Rosellini Scientific builds an active market for translational medicine that connects buyers, sellers and inventors. Visit http://www.roselliniscientific.com to learn more.